Lithium Carbonate Capsules

Risk of lithium toxicity (esp. recent febrile illness, acute ingestion, volume depletion/dehydration, impaired renal function, cardiovascular disease, changes in electrolytes). Maintain adequate fluid and salt intake, esp. with sweating, diarrhea, infection, or fever. Monitor serum lithium levels frequently (toxic and therapeutic levels are close); draw blood for serum tests 12hrs after previous dose. Monitor serum lithium, electrolytes, and renal function prior to and during treatment. Monitor thyroid function prior to initiation, at 3 months, and every 6–12 months during treatment. Monitor serum calcium levels regularly. Discontinue if diarrhea, vomiting, tremor, ataxia, drowsiness or weakness occur. Avoid in Brugada Syndrome. Severe renal impairment (CrCl <30mL/min): not recommended. Elderly. Neonates. Pregnancy: monitor; discontinue or reduce dose 2–3 days prior to delivery. Nursing mothers: not recommended.